The drugs industry is an enormous multibillion businesses encompassing an immense number of companies involved in the design, production and marketing of drugs worldwide. According to the type of drugs the market can be dived into the following segments: diabetes, antifungal, antidepressant, antithrombotic, hepatitis drugs, analgesics and a far more.
Currently, the drugs market is undergoing a recovery phase in the wake of the recent decline provoked by the economic slump. The market growth is spurred by increasing demand for drugs across the globe, rising incidence of chronic as well as infectious diseases, population ageing, product innovations and constant technological advancements. North America and Europe are the most prominent regional markets. Bristol-Myers Squibb, Pharmacia, GlaxoSmithKline, Merck & Co, Novartis, Eli Lilly, Pfizer, Johnson & Johnson, Allergan, Schering-Plough, Bayer and Abbott Labs are amid global drugs arena giants.
A huge collection of the research reports covering the drugs market at different geographies can be found under this MarketPublishers’ catalogue. The researches provide comprehensive assessment of the market, characterize major market trends and disclose essential market indicators. The reports describe the competitive scenario and indicate top market players. In addition, future prospects for the drugs market are thoroughly studied in the research reports.
Publications found:
9,295
Sort by:
16S Ribosomal RNA (16S rRNA) - Drugs in Development, 2021
US$ 3,000.00
16S Ribosomal RNA (16S rRNA) - Drugs in Development, 2021 SUMMARY 16S Ribosomal RNA (16S rRNA) - Drugs in Development, 2021 provides in depth analysis on 16S Ribosomal RNA (16S rRNA) targeted pipeline...
April 2021
85 pages
23S Ribosomal RNA (23S rRNA) - Drugs in Development, 2021
US$ 3,000.00
23S Ribosomal RNA (23S rRNA) - Drugs in Development, 2021 SUMMARY 23S Ribosomal RNA (23S rRNA) - Drugs in Development, 2021 provides in depth analysis on 23S Ribosomal RNA (23S rRNA) targeted pipeline...
April 2021
70 pages
Acute Bronchitis (Respiratory) - Drugs in Development, 2021
US$ 2,000.00
Acute Bronchitis (Respiratory) - Drugs in Development, 2021 SUMMARY Acute Bronchitis (Respiratory) - Drugs in Development, 2021 provides an overview of the Acute Bronchitis pipeline landscape. The rep...
April 2021
30 pages
Adenocarcinoma (Oncology) - Drugs in Development, 2021
US$ 2,000.00
Adenocarcinoma (Oncology) - Drugs in Development, 2021 SUMMARY Adenocarcinoma (Oncology) - Drugs in Development, 2021 provides an overview of the Adenocarcinoma pipeline landscape. The report provides...
April 2021
100 pages
Adenosine Receptor A1 (ADORA1) - Drugs in Development, 2021
US$ 3,000.00
Adenosine Receptor A1 (ADORA1) - Drugs in Development, 2021 SUMMARY Adenosine Receptor A1 (ADORA1) - Drugs in Development, 2021 provides in depth analysis on Adenosine Receptor A1 (ADORA1) targeted pi...
April 2021
45 pages
Ageing (Other Diseases) - Drugs in Development, 2021
US$ 2,000.00
Ageing (Other Diseases) - Drugs in Development, 2021 SUMMARY Ageing (Other Diseases) - Drugs in Development, 2021 provides an overview of the Ageing pipeline landscape. The report provides comprehensi...
April 2021
105 pages
